COMPASS PATHW SP.ADR Cash Flow Conversion Efficiency
COMPASS PATHW SP.ADR cash flow conversion efficiency. Based on the latest financial reports, COMPASS PATHW SP.ADR (5Y6) has a cash flow conversion efficiency ratio of -0.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-40.31 Million ≈ $-47.12 Million USD) by net assets (€84.53 Million ≈ $98.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of COMPASS PATHW SP.ADR (2021–2025)
Cash flow conversion efficiency of COMPASS PATHW SP.ADR from 2021 to 2025. This chart illustrates how COMPASS PATHW SP.ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for COMPASS PATHW SP.ADR for real-time trading data and today's change.
COMPASS PATHW SP.ADR Cash Flow Conversion Ratio Explained
COMPASS PATHW SP.ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
COMPASS PATHW SP.ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COMPASS PATHW SP.ADR ranked by their cash flow conversion efficiency. Also see COMPASS PATHW SP.ADR stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Union Holdings Ltd
SHE:000036
|
-0.005x |
|
Great-Sun Foods Co Ltd
SHG:603336
|
0.091x |
|
Grand Pacific Petrochemical Corp
TW:1312
|
0.073x |
|
IRESS LTD
F:BRF
|
N/A |
|
Liberty Broadband Srs A
NASDAQ:LBRDA
|
-0.012x |
|
Biotest Aktiengesellschaft
XETRA:BIO3
|
-0.114x |
|
Chapters Group AG
XETRA:CHG
|
0.040x |
|
Zhejiang Yonggui Electric Equipment Co Ltd
SHE:300351
|
0.002x |
Annual Cash Flow Conversion Efficiency for COMPASS PATHW SP.ADR (2021–2025)
The table below shows the annual cash flow conversion efficiency of COMPASS PATHW SP.ADR from 2021 to 2025. Review COMPASS PATHW SP.ADR (5Y6) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-52.85 Million ≈ $-61.78 Million |
€-157.24 Million ≈ $-183.83 Million |
2.975x | +486.18% |
| 2024-12-31 | €154.69 Million ≈ $180.85 Million |
€-119.19 Million ≈ $-139.34 Million |
-0.770x | -78.61% |
| 2023-12-31 | €225.74 Million ≈ $263.92 Million |
€-97.38 Million ≈ $-113.84 Million |
-0.431x | +25.85% |
| 2022-12-31 | €181.28 Million ≈ $211.94 Million |
€-105.45 Million ≈ $-123.28 Million |
-0.582x | -144.21% |
| 2021-12-31 | €284.41 Million ≈ $332.51 Million |
€-67.75 Million ≈ $-79.20 Million |
-0.238x | -- |
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more